Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) was down 0.4% during mid-day trading on Tuesday . The stock traded as low as $6.60 and last traded at $6.76, with a volume of 88,290 shares changing hands. The stock had previously closed at $6.73.

Several equities research analysts recently issued reports on FOMX shares. Guggenheim reissued a “buy” rating and set a $10.00 price target on shares of Foamix Pharmaceuticals in a research report on Tuesday, May 10th. Zacks Investment Research lowered Foamix Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th.

The stock’s market cap is $202.03 million. The stock’s 50 day moving average is $6.57 and its 200-day moving average is $6.59.

Foamix Pharmaceuticals (NASDAQ:FOMX) last released its earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.08. On average, equities research analysts predict that Foamix Pharmaceuticals Ltd. will post ($0.89) earnings per share for the current year.

An institutional investor recently raised its position in Foamix Pharmaceuticals stock. Tekla Capital Management LLC boosted its stake in shares of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) by 6.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 652,145 shares of the specialty pharmaceutical company’s stock after buying an additional 38,568 shares during the period. Tekla Capital Management LLC owned 2.13% of Foamix Pharmaceuticals worth $5,289,000 at the end of the most recent quarter.

Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Company operates in the segment of development and commercialization of foam-based formulations.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.